In the evolving pharmaceutical launch landscape, speed is no longer the sole predictor of success. Over 50% of U.S. product launches fail to meet sales forecasts, largely due to outdated strategies focused on clinical novelty rather than genuine market needs. Companies must now prioritize go-to-market (GTM) models that address unmet customer needs, emphasizing a consumer-grade experience.
Six key forces are reshaping pharmaceutical GTM strategies: increasingly high consumer expectations, a shift toward prevalent disease treatments, rising R&D costs, intensified competition, changing policy dynamics, and the impact of AI technologies. Brands that succeed will be those that integrate robust evidence of value, deliver seamless patient experiences, and engage proactively with payers.
Ultimately, pharmaceutical companies must rethink their launch strategies to focus on what stakeholders truly value, highlighting differentiation, evidence generation, and user experience, rather than simply striving for a first-to-market advantage.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.lifescienceleader.com/doc/how-pharma-go-to-market-strategy-and-launch-readiness-are-transforming-0001
